Author Archives: admin


Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine …

MIAMI (PRWEB) November 11, 2014

GlobalStemCellsGroup, Inc. has announced plans to host a minimum of four international symposiums on stem cell research in 2015. The symposiums will be held in three Latin American countriesChile, Mexico and Colombiain which Global Stem Cells has established state-of-the-art stem cell clinics staffed with expert medical personnel trained in regenerative medicine, through the Regenestem Network.

The fourth symposium will be held in Miami.

The decision follows the success of the Global Stem Cells Groups first International Symposium on Stem Cells and Regenerative Medicine, held Oct. 2, 3 and 4 in Buenos Aires, Argentina. Global Stem Cells Group CEO Benito Novas says the Buenos Aires event, combined with its steady growth of new clinics throughout Latin America, has provided additional motivation to schedule more stem cell symposiums in an effort to further educate the medical community on the latest advancements in stem cell therapies.

Thanks to Global Stem Cells Groups growing network of world-class stem cell researchers, treatment practitioners and investors committed to advancing stem cell medicine, the company is rapidly moving closer to its goal of helping physicians to bring treatments into their offices for the benefit of patients.

More than 900 physicians, researchers and regenerative medicine experts from around the world attended the Buenos Aires symposium, and Novas expects that number to grow with upcoming conferences.

We will continue to bring together a variety of committed stem cell advocates from the U.S., Mexico, Greece, Hong Kong and other regions around the globe, to be joined by a team of knowledgeable speakers, each one presenting the future of regenerative medicine in their field of specialty, Novas says.

Regenerative medicine as a field is still in its infancy, according to Global Stem Cell Group President and CEO Benito Novas.

Our objective is to [open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point of care medicine to the best of out abilities, Novas says. Our mission is to bring the benefits of stem cell therapies to the physicians office safely, efficacy and compliance with the highest standards of care with safety, efficacy and complying with the highest standard of care the world has to offer.

The purpose of each symposium is to bring top stem cell scientists together to share their knowledge and expertise in regenerative medicine, and begin the process of separating myths from facts when it comes to stem cell science and technology.

Read more:
Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine ...

Stem cell treatment for Rafas back problem

BARCELONA, SpainRafael Nadals doctor says the 14-time Grand Slam winner will receive stem cell treatment on his ailing back.

Angel Ruiz-Cotorro told The Associated Press by phone on Monday that we are going to put cells in a joint in his spine next week in Barcelona.

The Spanish tennis star was already sidelined for the rest of the season after having his appendix removed last week.

Ruiz-Cotorro, who has worked as a doctor for Nadal for the past 14 years, said Nadals back pain is typical of tennis players and that the treatment is meant to help repair his cartilage and is similar to stem cell treatment Nadal received on his knee last year.

He said Nadal, now 28, is expected to return to training in early December.

Several NFL players and baseball players have received stem cell treatment. Nadals fellow Spaniard Pau Gasol, center of the Chicago Bulls, received stem cell treatment on his knee in 2013.

Nadal experienced severe back pain during the final of the Australian Open in January when he lost to Stanislas Wawrinka.

[Nadal] has a problem typical in tennis with a back joint, he had it at the Australian Open, and we have decided to treat it with stem cells, Ruiz-Cotorro said.

The Mallorca island native has struggled with injuries in recent years. A knee injury caused him to miss several months in 2012. AP

Complete stories on our Digital Edition newsstand for tablets, netbooks and mobile phones; 14-issue free trial. About to step out? Get breaking alerts on your mobile.phone. Text ON INQ BREAKING to 4467, for Globe, Smart and Sun subscribers in the Philippines.

See more here:
Stem cell treatment for Rafas back problem

Stem cell research may lead to cure for Type I diabetes …

DEAR DOCTOR K: My teenage daughter has had Type 1 diabetes since she was 8 years old. Fortunately, exercise, a good diet and insulin treatments have kept her healthy. I recently heard of a breakthrough at Harvard that might someday cure Type 1 diabetes. Can you explain?

DEAR READER: The research youre referring to was conducted in the Harvard laboratory of Dr. Douglas Melton. Like you, Dr. Melton has a child with Type 1 diabetes. When his child became sick, he redirected his laboratory to the goal of finding a cure.

First, some basics. When we eat, sugar (called glucose) gets absorbed into the bloodstream. Almost every cell in our body needs glucose to function normally. However, the cells prefer a steady level of glucose in the blood not too high, not too low, but just right (like Goldilocks).

To keep the glucose level steady, the pancreas a finger-shaped organ in our abdomen makes insulin. Specifically, when we eat and blood levels of glucose rise, cells in the pancreas called beta cells make insulin. Insulin drives glucose from the blood and into cells throughout the body. This lowers blood levels of glucose.

Type 1 diabetes is an autoimmune disease. For reasons that remain unclear, the immune system attacks and kills beta cells. As a result, people with Type 1 diabetes no longer can make their own insulin. Without insulin treatments, blood glucose levels rise dangerously high, and other damaging changes occur in body chemistry.

People with Type 1 diabetes require insulin every day to remain in good health. The discovery of insulin treatment for diabetes (in part by scientists here at Harvard) was a Nobel Prize-winning accomplishment. But it was not a cure. For years, scientists have dreamed of somehow replacing the beta cells that have been killed by the disease.

The discovery of stem cells cells that have the potential to develop into different types of body cells was exciting for medical research. Among other uses, stem cells theoretically can be coaxed into becoming cells that have been killed by disease like beta cells in Type 1 diabetes. However, until now, no one has figured out a technique for transforming stem cells into beta cells, in the large number required to replace the beta cells killed by the disease.

Dr. Meltons team seems to have accomplished that feat. They have been able to create billions of beta cells from one persons stem cells. When the cells were placed inside diabetic mice, they started making insulin in just the right amounts: Blood levels of glucose were not too high, not too low, but just right.

It will be years before we know if this treatment will work in humans. If it works in the short-run, will it continue to work will the cells truly produce a cure?

So while this research does not represent a cure, it is likely to be a landmark event on the road to a cure.

See original here:
Stem cell research may lead to cure for Type I diabetes ...

Alpha Stem Cell Clinics: Delivering a New Kind of Medicine

4u]6 endstream endobj 637 0 obj >stream Hj0~ Cqv1Xpl%3,QC~:?[>27C 8Bc u6{Wn7:gZk"W8'4 xdtN=$cM0.zuFTu%@"($O~p_7MeLq'{(0KdkJ1PQ?o endstream endobj 638 0 obj >stream HtTMs0WQ qLL{p9L vj>=A0)S^ UM&W:j1NEPk*5x$_uiNz*&Y R8J 5QD!ekV;EF#Nm*U34DxE/`uR[0n@J_"vM[h ~ZNhE& fz#)&~p !RG3m,Abb)OFchQ"y8T_w'i&Ql+a^J-i5wj8)x3nDGM[H,&/m vijH' '60kd7O@r 3Lr8CV2`~`=G,#@lsq:jrq9VBN](`&B2CLOAw endstream endobj 639 0 obj >stream HtTM0+hWC.H=VU@ 0bew8 =d4Ki`ptQ^/@8Xe*lrJvX{dSWBx-b UG#B(/Bpj75GndleCYGN9htl`E *CD)_ qsBF}dov_jF' #0h;IT]MDl#x$~/#:{?^H#i-VwX4DnbFoL91Ms^L|mvZ ]yTZDE{u7w HJ'(/y^[IK+NTky(#WEHX3R;3-$T66-v+D| '*u> endstream endobj 640 0 obj >stream HdSR0+2Y$3 .tt:uaGdr_N%kQNS_U ':a*~UtvhDO]5* q"@j3[l!Zp YlEKU(OvJ%E@:Ka-yXB2vnKl'FA127f:[`e+qwo #XR!Q;~:lD*Rxd| UE;g-C yVA7'ikn7}ji6 8l`: g7L Q8.+@;BA6nZBsKVZr,+>stream HV{t]@6 2!CGf# l^` H6C!Pi"mE E=rl(ZE*"Hswf}oHD3$M_NgZByzzRXd~ 1SDS*+gzXW6,YzUb'q'C" uvIpuHR4?eg]@.)gi+T8!-NNJ6qUGv=nG"j1|gmO:K1yM]=0(vWYXSrOB>Ph/ X0W('aC_c7]dg,IcXCH| p3yMcx HnD/ N4Z>7# .v6c5|?vz:iR1ME@d~kEyO3K'Jz8*C#c-L[z 7!>e+;N(iS!i ztNUZX1]Q[!"$QH.$S|_2E *+CyO|T:5m+5Blne5~ W5:F15qsFkgU5Dyq[89q7qcOD9N+i 5u16Y8Y/b,v]UJLsBn/r6"YS*_0P 31u-6Vim&g^;6" }&,Hig+PDP`)wh-C4h.^r3RTJeo )l[E,n?h*EyER,NKQmr,p$3jrd[3&]^xf;bq|wWVf*;vW+~`aCwHOK}z8{LJLTE BW/ hFvPI-YG04v1@Lnf,.KrjE(f-(1Dk8XW'Gh5JW6/= y$$2_oPb3 "QzHK >oI3 ;BG91v1lxQ+ oYN]w~`X7rsE^S8[F/.AP.e- _Pq~C,M]Mkx@N> Hpdwx ?JbO-:ct2el_do]Vj8:5[ouivpVEYp87N*"nP9*AdUqZHpUn9U8E q3.+|VU>{_u1QQY-]%tW8V@6.`Y*lZ]WKI(''FDMMkZYP>O$4/RmkSn;Igs9wJE-[b(,RjiCZo[[]79*.--*-&NX7I2p^AgNBfgQTCRf]YbYUp~GO0_ms?wsujd2V;(H5s~rp}!}m a.[NSD"*zyZZ#N+aew|Pdo~mD0xX/'~?gur5-lF"t2,{p0:O9oeaMXJ'oDK8vpenH$~!choR|tj|ST&|@ ?TJtz250caozz1uOoiCEm#mgd&d-RTBte>z5Vbm7csUjUka=TyA^Z jjJi ~J1IU-G-Jdhhm&W /;Bvc7?&qY3H +U%ny#y M7qD:G6E^d i7zx7j4,{Vu2*)%$(%$W(r%+"%H6Qg *tG?l$K*VLRh@j2FJl|Y>(9R5z dZSz 9HBi}d 2S`*lC :GNfN6pJqR Mrm: Rmp0;=UV!tns^jY~wEc8G3?q1#uh!96o+OPE)Mb{4y#2psgGx'hdl/p]J0> >%d]t}yU+t?+;N9tf|7y Msk{ uGn/W?L&2+6g` endstream endobj 642 0 obj >stream HyTGz{ET"W4j4 Q{4jbL4"F]:jQ#S{oW_U_7QCzP_tlbLg)Dk~|4CZK5@#z}F$L/&YX;`vv_*v4h0Y#&x` uBRlp8 n!BT1&&1.. Ng-Sr[5uHMdU2WL3k&`r'h0u2(Mep+1NXeMATL`)KVx=Mwes%;"O6k("SeH9QI(VCiFZIDX,3-Us|}}vF-C%_ 4sPD^bS^) K+Oh&{:`V8([Yrv+^dXbf+}o;efhKL};vYL{'p(sTLCQ*LF_nq[eyyDrYNrTPfE93Cqow`;}qOuk"l_ RU&"Ea/-(Y*|X6 Mh4N]nbZbZa/Zc`? Qtqt ExhC7tY9DOy7bx1H};7b&qqMDxQx1c)xT /1?cdLQ3Mh*Ah4[()%Q2e_R R}~4s@)q$ouni*4nLi-i!}aA_pKZKnM }mknGK8r{;;iwV*JYnslA'z:4z5h+oeZ%j 799-QmwN8I{ywN9n|9vu!1 )l"gK8@ "5 #(D#8".!L73L36s37B,6KR|i+|mXVc% 7+]WYiV!^*i3@+R_'E7"H*Dp]+"EUlXE"ZXqAxqQ "QWDH)Hi"]dL%E&rE@"Q,JD(BT*Q-jD qSc89^NmqG}@i pAh-SH3uSI7Hh0 4fKh q4&$LSh*C{>}@G1}B9M/hY4BZDKm&Svnl7v1?jM 0&D sne92wJj)p " @sGDBA)B)hmmvNEi}A:DctNI:E;y'y7Gt.Q%eBIL)tR))2))Q.Q>P!Q1P)Q R%SUS]t]E77I1)2nJM)3b!#e*L49gjM3M6&1I:h:m nF"7N:_:[dnSU_eSY4vt:u&bl6:kV

M- Pp ::zzcbcbcF-hXxLDLdLTw.#|O)>/0300s00K%cJ|?;Va5?O_3~X [;{49]9O.L.+JyU}/S2M(O2C,3/2KWkjUeM @mj,Re*K6Y2CBjR{e'k~Y:uP^W uXTG-uTVuU'=uRWuZ>Tn:#+wDyS>S^/YR||SWT= R VUjBUCpXE&j"U3hU.OVm01S@ZW~K/pvO=vO{ rtE{bL 7E&72M9dbL5M9bQ`Ds$&4)I5M9cYa5Yk.Ls3zsl0WFdbmnn2Mcr]3m%5yygygxx=ywy_q?s r11 Z'xx!rJQ:_`) MZ' 9q `0`I~_/+bs1YX}y=g;e_/72Osef/v{>w|88I)xR[-xKKJ^H~s2eKy,bVz`kq@lXJk p+" h+x+Jd+Jt///K%zI^zi^aPIc/Vpo@$ea2FH%eq2^&D$eLi2]fL%ey2_BY$e,e,!VJY%%T$"$R$Zb$V$^$Q$YR$U$]2dLY'elMYV&edIN%[dK}R(E_A9$rXQ9&SrZY9'\+Q*|!7Nm#w'KoZG%@X( JYxoMAa0( A |(G9GT*]*{*jZ:z>D4D#4GM-m]= >g^>~A!a1q I)iY9yXEX%XeFcVbV#aG"h qGd iHG`-2 [ YFvbry|`/E8C(aqB0'p"('qb8'I$'IqR4'p8kLglt648-Vgd$N+kkkkz9mmA;j']vC?O3Ot:Lt:NtN:Mt:O]t.L5D ]tjkFjFkjk&j&kjktnI7t,4Wwk|-OH=X=*vU]ak:v]]~n`7&vSna[6?WyxSU?// PNi$J@Y+BmR(BZR(UMv (:qq@QGVd*0x^}}_{gs//)p=:#R ittAWd2#=nd#}A.c@B>!g1a8F`$Fa4y8xS00300s;QB~r;N8$Nvq{9;qwt]9q&?9{pOvs6p/}/cr^9MeVY3"S1Ru/}4 " SQvp8v{A=Yazy3$T.0r{jgOx1Gi@lJ3hCE}ipF*Z]96RB/LZnF 5 ]lmjN4tK%"|Z"A$9j;5CT`kfdec9W5MPZFJ;k`wMZ;O"6JxqH(G ?zr.0N*n);w@12KSKk%HRY'd8(4^ umW(p%>s)9WImb%-UlJ*qJ=c:$mm;]H:(h{}j{4UNr&I mfeBN+)kj% "AvwZ*#r!woP C &%pr]/~_W7m6m/M2((ct>tKesjsuzJb~JdlFci9fF2'L)*/FZzi {oMirbN_>{dgwNCJh6O?G[l-*:SlBiTp[e7-LEiw%gkEhj4_qr8;zLGml&f'UXt{5VFI(BxGniv&7(4*9E#k.V/&j14zES"4v| ]d}b.`S:~?Jin!!P@E!5RS'%B]mT=LWKw7X"qNDgk`G, ,+sB3'ks5*5/uzs{55WHvweILIt;=yvW/s]#3EOto~G/L^dlVKFX6l~lB{)Hqr5YKSW`5zI,kSj/~BpHv$?T,]tV[z|)z)Ks|l5n]C~bW/sYUg??1^umdU83'&{l';K%ufB8v)[Kv[$,vPQe}XH@WJDi%xD%$Pi3{ssqU.*r5pOJ^Q|ZAU5W1IA=Avg :3W.rz/ [9S^G3R/3h=[J'P1$T6wEd9(uLFpAE'}L:YQ)7URO{D/SKO?O9^'-)ozq^ >McZQ6H e*d,q [+yRa?J@0:8/o^QU0@$[JeKYA(>=/@!|`^ jwKygJmFdP*x""N>!CxCFh4vS.KYK-+cEd xf(Xm!me"5kk"ePm0v3hL0WE.(KS|T(-JKmr6j0>Q 7a,!9DJtT ><_ v="" ku=""/>

:/%ub ~Y6 "6S4'`yMQ" 6d4c44i idooE3VtU`Qh+ Ma[YSGx54'F V[SU(8|; Rvw2e!^c]CsC:Jp;11!eP8-O---OX8E")FShz9?"6PAF3rOGQXM2C?2^o,dOo$9nHMRt>c2wf)34Jvv82>hrlNtX+#krRMLQgz;aif=~;*rho5bx_/8 by8WzI51C 9 7FExG 5w0/wH$Ec|37a[A7x4N};9T%R.}p~+Cpexi$Wdu&[Ap!D+=`enq6dO[15 D4m:&Pa4J|[vGuhD $a8pqi>J |;Xx[k'Zh2}x]c4~;j?wtPej>5A>1=X@4,B7d*Nj7L&b&6w_HxafsLB6PgVO/uCjPZCt;GK7yCpL0;`yF;wc6bxm1 V~/mj>fe]oy/u>zO{W+iH#cjVog2H>N9`}h*I?OL=G:%wC&kXD7Z6]tPmb0M{P[]1j5?c;&nXC#y'$gq-3c oz_=nO*Dg2IT(+y?lf~Ht-W0F-* j~O3buSowOtGHD U.~? L1[m.zm+sZ@$!R.K7{&F%fH*zph)tmWyXY[/z#]CUw.2^or>+B|x0_~82_,o:X|;>L2#LJ%)A[Fv:)k)I:Qfl.WV_2'O$1AA){pxwW.@^&s* .& }Gwa~sS5WGyb6}uT92|.}~b2yE;} 0rn"@:A>sa,;_dU89iZDYy/s4E,~~NB4H/EdrFqp9/*()wg,5Lddy?Y` i7 ?-@YD]9@i WvEi)r7Lu 5Jf1Zc^l,8.,20>]T0H,HPM=?

j>DMCKpuCWw7?oikE7o6 @W.{uXAHH l6PPD KpT`T)WPyYpjG8=1`*5Q) ?kH@P8^ {*7)6tfjh(F{ra~n&c)r&:;+X!|U(2MCQpJ8{Zti{9:-Yo{uE?K{k|Ca=[LWgNnTn/1~zh v&Cl!)2C!i#d%Ekc%Ms $"[LI*H81IE@oFuB?U=X[f #8^d/:%0n)pW -oyXpJ@MTs^Wf;XsK9Gz5>>u@)$ o}uM|ey`{_;r,[WME]j6Xw=cUF4i{"E9-~EOcW#0`b Otffcq9U0"%R1"TJZu5s{zFzW=>xbmf-e~]?Yz!D^[%s3|s|9>}|b;%KqN[i6uFV]+^&e$~eAAcML4U0u TM4"?RO~lt0w;vj[-)%VQRz3v $@WcI[u-lVq+Z7:SgFn*sS=h0]`HJJ0VB@""zifAG2WM>T;(! x&=8_3.a*tq;lW6Rj@@~87{)*OCg%_xm`'":tqvO/FD}``$&'xh@;J@ h G ,E"!Zb1lYLI,gsuxKX+rnRNm%T8'g 9O>W@_al{B:&R(IA0IsRPtTzm V>U)ER&1xajU-i+n /k=fYlUCiq !E(7-fGcy,9salR7)n;R4X):Zu M n)e(2/2DRg h%Xt>x+xj}XM]VS=7Q}h>Gu3? m& u-=SI:8pk,.=KFqJ~,MZJ;/5|Iz=,lnc*=66u> "?rvvLfL:xRLh-SGg[JLadhD>"{(D`jC0>/ 7VEGL[iP&6Hhy>&=k"|A7Rz/$kJ2AhtEpQ2fOj%xGh9WK1V/?/^P@6 x l6nD^F+K@Sk$U6=t)*|"h1iZ;pk^`G/LHwt5{zAK{%(%ETjD32C:z_>kTa~,

6ow?(!B Jh} CO+M,pny: {tFY=:S8hr2n7j+zSc (|V;g3&oLB}F| /E21xgx)6mk{?Fn7a>J*I%yVlnBe#""T(XxU53#^W&_fp$nBC`h|oKz8b=1::w&AN=3! lsqAc|3Gui}A;6%47S;G /1K/~x)6vPfr s:7;:J_O0o.Ey3gu*MyP,v )p5U~5"?uc"MO0%9&YKXcjt:l uPz@:c%>n%k5qi>/3tb*HL;tuVPhI.;X7.U_S&h&b,l5-{O*2GY"3d'*eVJ_jlVF8Kk::cW@>$_H-2ZnT9g8.[8kQ"H=&oBhGF|}8+>Fe SM&sB8=&<51TuFm?4]`=?!}>7CL.mWCe+J<|M)&)QE~R+}Y|dO#%?ZSy8C"vQ^CGER&)e@'/Fz/~-C uRZEY8Dy}9fT .NmdW!m|dr7}O=D~&3IwTyyv`zTI0v35r8G8a{k~+ag"_.hBndbx^b)d&R#pkH6MBB1PkX;o2J3/Su_2#FZ:LN5 `*hN39xGo@lZ5pV%r~[V.c]-a}wC]Hw?y~yAz6t:n,G <[ PodwEd82s YWg`_E'nQ[`Gsb)TO(>rKz n)UDzX98G?3/V/C!O[1<}PdJ318I~};M&YYk #[9w#X_yS'P^N>)QCDuRz1~qQ$3%e4acsuPKe@}%Z? H2,>/d? d7A=$]|yXbYj$26vw&K])oXZdy:+h.8)2kZP]UiuGWBIjb&`Pj,-LukaU|"2jy%lQ 5c=g99a~!`6r1:2v,zOn27FI83OFmP%/$Y$`3i?;o#H;:>Q}e;2N|o9nUP#FA> M UwJeF:A7yd9!t{{C'+D$3>="e1*:cOy<.ue> <'YoOwSrD$<'UH<7IG$/>.3x{ ~!,gl)ywK_[!)9{[BOG06]xShg/'`602f/Ze9ImGq~ueL(OE.sE55:`k#PF|$~:c#d0T&97bvw1(qxjJ+5f^{e/p>:K o::wO?';%. ]GNZ-u:3.K*No?6p7[-2R%|o 2`k`dnufL 'YgKoz;Ki?T&&^[.."/,`'G^J__HIQ%We38?qzY]] KX5|3@z8yOHI4o&n%^*pG"r{5m 8#^NqoVbcx@t?+ILTwd?U|!>K`1@mH2}HZf+u%;wJ{4TKvk{7qg"g1QZ6Qs|v/Zix3i?I-2^JA9-}(v@Y Dfjq-;$ts%}jYlJ8NS@~GQqo7w F$X L#wI$wpw v!UZa`B[8jNJ~>8H_2}{8y,Hy24mF3[Ic0U`}75uGl;F5P~o0uI}oYim*ka0TJ4zw"z.xmI/w0 Sj7l.`=ws>4}%R>)3b1 -.=aa,m$?/TbhMB 5A4+} DqHF"EKDx]Td8Ic]J7qn|Ozt)qO:;;bW5e?#q},8tBA9>.bUbGB4.gv7{N)L,A!czpg0dTemzn~_XP"`!(]i/Tx;;|vPtFnq{ROc!75cN68cq0gl{?*h$ ycn-/uw) kh>"a:HV;[h[ ZG3%iMS_Bo~&u/D)q^{j(w3|U@/@Fsq;8FLFuK=!J=I8=DQ"(3!(k6QnT6fp~N]Gj|!c|pyH{BfpXuS2*sO9L2)sXCT]e(_Vf2oI}CR[G;n>/uURWJmBjg>%IO@FeRJ}LSNCcZViS.dP`X `/8S~ yZm6hBZVj!Z-DhR bpFm7jQ1@4h. *@1h@R'hKTD[m/Xk-3y @WhGHI+iGTHD4hxlulvjil)e"SL ApQYG22sdK_0~. ddFC|5 gJ/)|1e#te/F{v(.Qt}e*wC>gt]Yl$Ts f+ _NU56mN@(U4JtTz+{nO9h.D@;07^.I`+@u+j$Qnmqut)Hp=(G658g(iEXeJX baThm")>gmJqJ _Q*%:[o5hj{U}i}m"yq58r1-h4:i"m"9*S 9HNCQd1SLK!$ G6q2+r;>M^&[BX^H;sG.BVdHD_"w-tHis.&8nD~k%T$5p*GR kDd|M&Y"M,0~VcoKevz[ SwZqjD/X.q1&qM6XB_,j!83=m-l^)+>BW}~mdXaH1n6>`g6t"$8@ n5uR?C}vOa}'2xVaPv}fcff`51|iN7n5:0H1R_A|&l/v%;UMv*)-u{J/E6H]oSj*7aBZa5i/f;J!nk%Ew7[2CMb[Qy*FyL&YexyF3fdc6o DGyc.!II1YRX/8d Z_#vIwcmy?l@a)ht=q7D[ Zu6a;E"lD7Sq%A.qO_u0pE{pg;mxLI0zA+h q*P Vpl'cg5>/4?)>O7?_q2?G0A>y?y.~/o ~|~;^Z?s|*% endstream endobj 643 0 obj <>stream Hj0 endstream endobj 644 0 obj <>stream HyTSwoc [5laQIBHADED2mtFOE.c}088GNg9w'0Jb 2y.-;!KZ ^i"L0-

Original post:
Alpha Stem Cell Clinics: Delivering a New Kind of Medicine

Minister: Drug administered to Lee Chong Wei by specialist sports clinic

PUTRAJAYA: The banned substance dexamethasone was not administered to Datuk Lee Chong Wei by doctors at the National Sports Institute (ISN) but from a specialist sports clinic as part of a stem cell treatment for his injury.

Youth and Sports Minister Khairy Jamaluddin said it was usual for national athletes to be referred to the Kuala Lumpur-based clinic for specialised treatment such as stem cell procedures.

"There are times when ISN refers our athletes to the private specialist. The doctors at ISN did not administer dexamethasone to the athlete but it was done at the clinic," he said after attending the launch of the GeNexter Carnival 2014 yesterday.

He said the use of dexamethasone was allowed, but only when athletes were "out of competition".

"Many athletes use it outside competition and it usually lasts about 10 days in the system. However, we do not know why it was still in his body," he said.

Chong Wei had reportedly suffered an inner thigh injury and sought stem cell treatment in July.

Last week, Khairy had said that an investigation on the shuttler's medical history revealed that dexamethasone was administered into his body on July 17 to treat his injury.

Chong Wei, 32, pulled out from the Glasgow Commonwealth Games from July 23-Aug 3 to recover from the injury for the Copenhagen World Championships from Aug 25-31.

He was tested positive for dexamethasone during a random doping test at the world meet.

Results of a second test done in Norway had returned positive, resulting in a temporary suspension of Chong Wei pending the outcome of a Badminton World Federation hearing.

Read the original here:
Minister: Drug administered to Lee Chong Wei by specialist sports clinic

Specialist clinic gave Lee banned substance

Putrajaya - The banned substance Dexamethasone was not administered to Malaysian badminton star Lee Chong Wei by doctors at the country's National Sports Institute (ISN), but by a specialist sports clinic in Kuala Lumpur as part of stem-cell treatment for an injury.

This was revealed by Youth and Sports Minister Khairy Jamaluddin yesterday.

"Dexamethasone is allowed for athletes seeking treatment for injuries," he told reporters after attending the launch of the GeNexter Carnival 2014 in Putrajaya.

"It usually lasts in the body for 10 days. But, in this case, we are not sure why it lasted longer than that."

He said that it was the ISN that had referred Lee, the world No. 1, to the clinic.

The shuttler took to Twitter on Saturday, posting a link to an interview in which he describes himself as "devastated" by the allegations.

"Thank you for having faith in me. I never cheated nor will I rely on banned substances," the 32-year-old wrote in the post. "There are so many unanswered questions and I hope to clear my name soon."

Lee - who is facing a suspension of up to two years, which could mean the end of his career - is awaiting a hearing by the Badminton World Federation (BWF). No date has been set.

Referring to the BWF hearing, Mr Khairy said that preparations are being made, with updates to be given in due course.

Lee tested positive for dexamethasone during a random doping test at the World Championships in Copenhagen in August.

Original post:
Specialist clinic gave Lee banned substance

Stem cell therapy for sidelined star Smoko

Magnifisio dashed home strongly over 1400m to win Saturdays Lee-Steere Stakes at Ascot. Picture: Westernracepix

Sprinter Smoko will have stem cell therapy at Murdoch Veterinary Hospital to a strained suspensory ligament in his off-foreleg.

Vets found Smoko had strained the ligament when he pulled up sore following his shock sixth as a $2 favourite to Shining Knight in last Tuesday's Colonel Reeves Stakes (1100m) at Ascot.

Co-trainer Ross Price said Smoko would be sidelined for months.

"He will go to Murdoch where they will look at him and see about stem cell therapy," he said.

"In about 10 days we will take him up there and see what they can do. It is then going to be five months off and hoping."

Smoko was a $6.50 chance in Saturday week's Winterbottom Stakes (1200m) before he was scratched. WA's hopes of winning back the Group 1 weight-for-age hinge on Magnifisio, Shining Knight and Testamezzo, with Barakey in doubt after struggling to recover from a virus.

"He is still feeling flat and I will have to wait and see if he improves over the next few days," trainer Jim Taylor said.

Magnifisio firmed from $12 into $8 on the TAB yesterday following her strong win at her debut over 1400m in Saturday's Group 2 Lee-Steere Stakes at Ascot.

Melbourne sprinters Angelic Light, Moment Of Change and reigning champion Buffering dominate betting at $4.30, $6.50 and $7.50.

View post:
Stem cell therapy for sidelined star Smoko

Family's desperate bet on a diabetes cure

The day Olivia Cox was diagnosed with Type 1 diabetes at age 16, her mother vowed to find a cure.

"I said to her, "there's someone walking this Earth who has been cured of diabetes, and I'm going to find him," Ruth Cox said.

Cox's search started with a call to Harvard University and ended with a family trip to Lima, Peru. It was at a clinic there that now 18-year-old Olivia and her father, Jeff, 54, who also has diabetes, received an infusion of stem cells designed to wipe out diabetes in their bodies or, at the very least, lessen its impact. The treatment illegal in the United States cost $70,000 for both father and daughter. Two months later, the Niskayuna family is waiting for a transformation and wondering if, in their desperation for a cure, they were snookered by false promises.

Because stem cells can be programmed to become anything from heart muscle to toenails, stem cell therapy can hypothetically be used to treat anything, from baldness to Lou Gehrig's Disease. But the study of regenerative medicine is still nascent in the United States, where it is restricted to procedures that use the patient's own cells, and it has been primarily used in treating cancer a procedure that saved Ruth Cox 13 years ago, when she had breast cancer.

Stem cell treatment using donor cells is more common elsewhere in the world, but with varying results and none that could be described as a cure. An executive order from President Barack Obama opened up funding for stem cell research and there are now more than 4,000 clinical trials under way, some on animals and some recruiting people with various ailments.

The American Diabetes Association strongly supports stem cell research, according to a statement posted on its website, which reads in part:

"Scientists from across the United States and throughout the world, including those involved with the American Diabetes Association believe that stem cell research, especially embryonic stem cell research, holds great promise in the search for a cure and better treatments for diabetes."

Jeff Cox, diagnosed with Type 1 diabetes when he was 11, has suffered none of the complications that often come with the disease neuropathy, loss of vision and heart disease. But Cox said living with diabetes is hell. He pricks his finger at least a dozen times a day to check his blood sugar level, because it is a more precise reading than the glucose monitor he wears. He also wears a pump that he programs to inject him with insulin automatically based on his diet and exercise each day. All the therapies used to treat diabetes are designed to intervene where the pancreas has gone awry.

In Type 1 diabetes, the pancreas doesn't produce insulin due to an autoimmune attack against the beta cell that produces insulin the hormone that converts glucose into energy our bodies need to survive. The Coxes didn't want their daughter to face a lifetime of managing her diabetes. They wanted a cure, and they were willing to take a risk to find it.

In order to treat diabetes with stem cell therapy, pancreatic stem cells isolated from umbilical cord blood that are programmed to produce insulin, plus autologous mesenchymal stem cells from the patient's bone marrow, are injected. Once in the pancreas, the cells are supposed to replicate themselves, gradually replacing the non-insulin producing cells in the host's pancreas. The treatment is conducted in Peru, China, Russia and India and elsewhere, but Zubin Master, a bioethicist at Albany Medical College, said the risks of traveling abroad for stem cell therapy range from paying for an expensive treatment that doesn't work, to cancer and death.

Go here to read the rest:
Family's desperate bet on a diabetes cure

Production of human motor neurons from stem cells is gaining speed

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Ccile Martinat CMARTINAT@istem.fr 33-603-855-477 INSERM (Institut national de la sant et de la recherche mdicale) @inserm

This news release is available in French.

The motor neurons that innervate muscle fibres are essential for motor activity. Their degeneration in many diseases causes paralysis and often death among patients. Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/AFM/UEVE), in collaboration with CNRS and Paris Descartes University, have recently developed a new approach to better control the differentiation of human pluripotent stem cells, and thus produce different populations of motor neurons from these cells in only 14 days. This discovery, published in Nature Biotechnology, will make it possible to expand the production process for these neurons, leading to more rapid progress in understanding diseases of the motor system, such as infantile spinal amyotrophy or amyotrophic lateral sclerosis (ALS).

Human pluripotent stem cells have the ability to give rise to every cell in the body. To understand and control their potential for differentiation in vitro is to offer unprecedented opportunities for regenerative medicine and for advancing the study of physiopathological mechanisms and the quest for therapeutic strategies. However, the development and realisation of these clinical applications is often limited by the inability to obtain specialised cells such as motor neurons from human pluripotent stem cells in an efficient and targeted manner. This inefficiency is partly due to a poor understanding of the molecular mechanisms controlling the differentiation of these cells.

Inserm researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/French Muscular Dystrophy Association [AFM]/University of vry Val d'Essonne [UEVE]), in collaboration with CNRS and Paris-Descartes University, have developed an innovative approach to study the differentiation of human stem cells and thus produce many types of cells in an optimal manner.

"The targeted differentiation of human pluripotent stem cells is often a long and rather inefficient process. This is the case when obtaining motor neurons, although these are affected in many diseases. Today, we obtain these neurons with our approach in only 14 days, nearly twice as fast as before, and with a homogeneity rarely achieved," explains Ccile Martinat, an Inserm Research Fellow at I-Stem.

To achieve this result, the researchers studied the interactions between some molecules that control embryonic development. These studies have made it possible to both better understand the mechanisms governing the generation of these neurons during development, and develop an optimal "recipe" for producing them efficiently and rapidly.

"We are now able to produce and hence study different populations of neurons affected to various degrees in diseases that cause the degeneration of motor neurons. We plan to study why some neurons are affected and why others are preserved," adds Stphane Nedelec, an Inserm researcher in Ccile Martinat's team.

Read the original here:
Production of human motor neurons from stem cells is gaining speed